Ongentys (opicapone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES: IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP				
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL DISPENSING INFORMATION				
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):				

Prime THERAPEUTICS*

Continued on next page.

Ongentys (opicapone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
☐ Idiopathic Parkinson's Disease	ICD-10:		
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A	
Clinical Information: Is this drug being prescribed to this patrial? Yes No	itient as part of a treatment regimen sp	ecified within a sponsored clinical	
Has the patient had the diagnosis of Id	diopathic Parkinson's Disease for at leas	t 3 years? 🗆 Yes 🗆 No	
Does the patient have atypical parkins syndrome? Yes No	sonism, secondary[acquired or sympton	natic] parkinsonism or Parkinson-plus	
Is patient's disease severity mild or m	oderate during ON periods? Yes N	o	
Is patient severely disabled or comple	tely disabled by their dystonia? Yes	□ No	
Does patient have severe and/or unpr	redictable OFF periods? 🗆 Yes 🗆 No		
Has patient been treated with levodo	pa/carbidopa for the past 12 months?	Yes 🗆 No	
Will patient continue to be treated wi	th levodopa/carbidopa while on Ongen	tys(opicapone)? 🗆 Yes 🗆 No	
Is the medication being prescribed by	a neurologist or in consultation with a r	neurologist? Yes No	
Has patient received any neurosurgica	al procedure for their Parkinson's diseas	e? □ Yes □ No	
Is patient experiencing greater than o	r equal to 1.5hours of average daily OFF	time per waking day? □ Yes □ No	
Has patient been previously treated w	vith entacapone(Comtan®)? □ Yes □ N	o	
Are there any other comments, diagnosphysician feels is important to this rev	oses, symptoms, medications tried or fa riew?	iled, and/or any other information the	



Ongentys (opicapone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
Please note: Not all drugs/diagnosis are covered on all plans information is received.	s. This request may be denied unless all required	
ATTESTATION: I attest the information provided is true and the Health Plan, insurer, Medical Group or its designees may information necessary to verify the accuracy of the information	y perform a routine audit and request the medical	
Prescriber Signature or Electronic I.D. Verification:	Date:	
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.		

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management LLC
Attn: CP - 4201
P.O. Box 64811
St. Paul, MN 55164-0811